The LIFE study: The straw that should break the camel's back

European Heart Journal

Volumn 24, Issue 6, 2003, Pages 487-489

  Messerli, Franz H ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN;

AGING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; EDITORIAL; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE;

ANTIHYPERTENSIVE AGENTS; ATENOLOL; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0037343458     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00756-X     Document Type: Editorial

References (21)

1. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
2. Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 2002; 359(9324):2203.
3. Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
4. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med 1970; 72:813-22.
5. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
7. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995;273:1592-7.
8. Messerli FH. Antihypertensive therapy - going to the heart of the matter. Circulation 1990;81:1128-35.
9. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
10. Mathew J, Sleight P, Lonn E et al. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensinconverting enzyme inhibitor ramipril. Circulation 2001; 104:1615-21.
11. Stokes W. Treatment of hypertrophy of the heart. The diseases of the heart and the aorta. 1st ed. Dublin: University Press Dublin, 1853. p. 347.
12. Messerli FH, Grossman E, Lever AF. Do diuretics confer specific protection against strokes? Arch Intern Med, [in press].
13. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
14. Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. High Blood Pressure 1992;1:132-7.
15. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985;291:97-104.
16. Messerli FH, Grossman E. Letter to the Editor (Ko DT, et al., Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA, 288 (2002) 351-357). JAMA 2002;288:1845-6.
17. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly.? A systematic review. JAMA 1998;279:1903-7.
18. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317(7160):713-20.
19. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001;37:250-4.
20. Grees TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL, for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12.
21. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2002;359(9311):990-2.